

World Journal of *Gastroenterology*

World J Gastroenterol 2017 December 14; 23(46): 8109-8262



**REVIEW**

- 8109** Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer

Sipos F, Székely H, Kis ID, Tulassay Z, Múzes G

MINIREVIEWS

- 8120** Retreatment of patients with treatment failure of directacting antivirals: Focus on hepatitis C virus genotype 1b

Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M

ORIGINAL ARTICLE**Basic Study**

- 8128** Structural shift of gut microbiota during chemo-preventive effects of epigallocatechin gallate on colorectal carcinogenesis in mice

Wang X, Ye T, Chen WJ, Lv Y, Hao Z, Chen J, Zhao JY, Wang HP, Cai YK

- 8140** miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1

Liu XL, Cao HX, Wang BC, Xin FZ, Zhang RN, Zhou D, Yang RY, Zhao ZH, Pan Q, Fan JG

- 8152** *In vivo* hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis

Zhang GZ, Sun HC, Zheng LB, Guo JB, Zhang XL

- 8169** Pharmacokinetics and pharmacodynamics of Shengjiang decoction in rats with acute pancreatitis for protecting against multiple organ injury

Zhu L, Li JY, Zhang YM, Kang HX, Chen H, Su H, Li J, Tang WF

Retrospective Cohort Study

- 8182** Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease

Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, Imhann F, van der Meulen-de Jong AE, Pierik MJ, van der Woude JC, Dijkstra G, D'Haens G, Löwenberg M, Weersma RK, Festen EAM; PARELSnoer Institute and the Dutch Initiative on Crohn and Coliti

Retrospective Study

- 8193** Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?

Luu C, Amaral M, Klapman J, Harris C, Almhanna K, Hoffe S, Frakes J, Pimiento JM, Fontaine JP

- 8200 Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen

Futawatari N, Fukuyama T, Yamamura R, Shida A, Takahashi Y, Nishi Y, Ichiki Y, Kobayashi N, Yamazaki H, Watanabe M

- 8207 Diagnostic classification of endosonography for differentiating colorectal ulcerative diseases: A new statistical method

Qiu EQ, Guo W, Cheng TM, Yao YL, Zhu W, Liu SD, Zhi FC

Clinical Trial Study

- 8217 Characteristics of fecal microbial communities in patients with non-anastomotic biliary strictures after liver transplantation

Zhang J, Ren FG, Liu P, Zhang HK, Zhu HY, Feng Z, Zhang XF, Wang B, Liu XM, Zhang XG, Wu RQ, Lv Y

Observational Study

- 8227 Balloon dilatation for treatment of hepatic venous outflow obstruction following pediatric liver transplantation

Zhang ZY, Jin L, Chen G, Su TH, Zhu ZJ, Sun LY, Wang ZC, Xiao GW

Prospective Study

- 8235 Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China

Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B

CASE REPORT

- 8248 Are liver nested stromal epithelial tumors always low aggressive?

Meletani T, Cantini L, Lanese A, Nicolini D, Cimadamore A, Agostini A, Ricci G, Antognoli S, Mandolesi A, Guido M, Alaggio R, Giuseppetti GM, Scarpelli M, Vivarelli M, Berardi R

- 8256 Combined thoracoscopic and endoscopic surgery for a large esophageal schwannoma

Onodera Y, Nakano T, Takeyama D, Maruyama S, Taniyama Y, Sakurai T, Heishi T, Sato C, Kumagai T, Kamei T

LETTER TO THE EDITOR

- 8261 Extended pelvic side wall excision for locally advanced rectal cancers

Shaikh IA, Jenkins JT

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Antonio Macri, MD, Associate Professor, Department of Human Pathology, University of Messina, Messina 98125, Italy

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR
THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Yu-Jie Ma
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Ze-Mao Gong
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Jin-Lei Wang, Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
December 14, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Observational Study

Balloon dilatation for treatment of hepatic venous outflow obstruction following pediatric liver transplantation

Zhi-Yuan Zhang, Long Jin, Guang Chen, Tian-Hao Su, Zhi-Jun Zhu, Li-Ying Sun, Zhen-Chang Wang, Guo-Wen Xiao

Zhi-Yuan Zhang, Long Jin, Guang Chen, Tian-Hao Su, Guo-Wen Xiao, Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Zhi-Jun Zhu, Li-Ying Sun, Department of Transplantation Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Zhen-Chang Wang, Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

ORCID number: Zhi-Yuan Zhang (0000-0001-9947-9709); Long Jin (0000-0002-4742-6688); Guang Chen (0000-0003-1274-1677); Tian-Hao Su (0000-0002-5834-3669); Zhi-Jun Zhu (0000-0001-5719-5396); Li-Ying Sun (0000-0003-1101-7994); Zhen-Chang Wang (0000-0002-6748-0294); Guo-Wen Xiao (0000-0002-3679-8400).

Author contributions: Zhang ZY and Jin L contributed equally to this work; Zhang ZY, Jin L and Wang ZC designed the research; Zhang ZY, Jin L, Chen G, Su TH, Zhu ZJ, Sun LY and Xiao GW performed the research; Zhang ZY and Jin L analyzed the data; Zhang ZY and Jin L wrote the paper.

Institutional review board statement: This study was reviewed and approved by the Clinical Research Ethics Committee of the Affiliated Beijing Friendship Hospital of Capital Medical University.

Informed consent statement: Informed consent was not required for the study as the analysis used anonymous clinical data. Individuals cannot be identified based on the data presented.

Conflict-of-interest statement: The authors declare no conflicts of interests.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative

Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Long Jin, MD, PhD, Chief Doctor, Professor, Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, No. 95, Yong'an Road, Xicheng District, Beijing 100050, China. zhangzy@mail.ccmu.edu.cn.
Telephone: +86-10-63138454
Fax: +86-10-63138454

Received: October 20, 2017

Peer-review started: October 23, 2017

First decision: October 31, 2017

Revised: November 10, 2017

Accepted: November 22, 2017

Article in press: November 22, 2017

Published online: December 14, 2017

Abstract

AIM

To assess the efficacy and safety of balloon dilatation for the treatment of hepatic venous outflow obstruction (HVOO) following pediatric liver transplantation.

METHODS

A total of 246 pediatric patients underwent liver transplantation at our hospital between June 2013 and September 2016. Among these patients, five were ultimately diagnosed with HVOO. Seven procedures (two patients underwent two balloon dilatation procedures) were included in this analysis. The demographic data,

types of donor and liver transplant, interventional examination and therapeutic outcomes of these five children were analyzed. The median interval time between pediatric liver transplantation and balloon dilatation procedures was 9.8 mo (range: 1-32).

RESULTS

Five children with HVOO were successfully treated by balloon angioplasty without stent placement, with seven procedures performed for six stenotic lesions. All children underwent successful percutaneous intervention. Among these five patients, four were treated by single balloon angioplasty, and these patients did not develop recurrent stenosis. In seven episodes of balloon angioplasty across the stenosis, the pressure gradient was 12.0 ± 8.8 mmHg before balloon dilatation and 1.1 ± 1.5 mmHg after the procedures, which revealed a statistically significant reduction ($P < 0.05$). The overall technical success rate among these seven procedures was 100% (7/7), and clinical success was achieved in all five patients (100%). The patients were followed for 4-33 mo (median: 15 mo). No significant procedural complications or procedure-related deaths occurred.

CONCLUSION

Balloon dilatation is an effective and safe therapeutic option for HVOO in children undergoing pediatric liver transplantation. Venous angioplasty is also recommended in cases with recurrent HVOO.

Key words: Hepatic venous outflow obstruction; Pediatric liver transplantation; Percutaneous transluminal balloon dilatation; Pressure gradient; Recurrent

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Hepatic venous outflow obstruction (HVOO) is a rare and severe complication following pediatric liver transplantation that leads to graft loss in the majority of patients. However, it remains controversial whether stent placement or balloon angioplasty is required for patients with HVOO. This study reported our experiences with using balloon dilatation as part of the treatment for HVOO in five children subjected to pediatric liver transplantation, providing valuable information for the successful treatment of such patients. Balloon dilatation is an effective and safe treatment for HVOO in pediatric patients following liver transplantation, and re-venoplasty is recommended even for patients with recurrent HVOO.

Zhang ZY, Jin L, Chen G, Su TH, Zhu ZJ, Sun LY, Wang ZC, Xiao GW. Balloon dilatation for treatment of hepatic venous outflow obstruction following pediatric liver transplantation. *World J Gastroenterol* 2017; 23(46): 8227-8234 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i46/8227.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i46.8227>

INTRODUCTION

Liver transplantation is the most effective treatment for end-stage liver disease. In recent years, significant progress has been achieved in surgical techniques, immunosuppressants and operative care, which has led to the optimization of post-transplant outcomes^[1]. In an attempt to solve the shortage of donor organs and diminish the high mortality rate after re-transplantation, efforts have been made to develop liver transplantation techniques with reduced-size, split and living donor organs^[2]. Nevertheless, vascular complications are still the most significant determinant factor for graft loss, especially for those undergoing partial liver transplantation with living donor grafts, during which the use of short vascular pedicles complicates the surgical procedure. In particular, hepatic venous outflow obstruction (HVOO) is a profound complication of pediatric liver transplantation; it has a high incidence (4%-9%) owing to the smaller anastomosis diameter and size mismatch of the hepatic vessels between the donor and recipient^[3]. The treatments for HVOO in children after liver transplantation include surgical reconstruction, re-transplantation and endovascular angioplasty^[4]. Endovascular angioplasty, either *via* balloon angioplasty or stent placement, is a less-invasive therapeutic option compared with surgical approaches for relieving HVOO and has become the first-line treatment of choice in pediatric transplant recipients^[3,5]. However, it remains unclear whether stent placement or balloon angioplasty is required for patients with HVOO.

Therefore, this retrospective study was performed to evaluate data from pediatric patients undergoing endovascular angioplasty for HVOO after liver transplantation at our hospital from June 2013 to September 2016. This paper presents our successful treatment of HVOO in a series of five children using balloon angioplasty.

MATERIALS AND METHODS

Patients

Between June 2013 and September 2016, a total of 246 pediatric patients (< 18 years old) underwent liver transplantation at our hospital, including 149 living-donor and 97 deceased-donor transplants. Among these patients, five consecutive patients (four transplanted at our hospital and one transplanted at another hospital) underwent venography and manometric measurements due to suspicion of HVOO. Patients were suspected of having HVOO when they showed typical clinical signs or symptoms, including ascites, pleural effusion, or hepatomegaly. Enhanced computed tomography (CT) and/or Doppler ultrasound (US) were used to further detect hepatic venous outflow abnormalities. Abnormal Doppler US images included an undetectable flow signal, a persistent monophasic waveform, a slow flow of < 10 cm/s, or a reversed flow

Table 1 Demographic data of the five pediatric patients

Case No.	Gender	Age	Original disease	Type of transplant	Graft type	Onset after transplantation (mo)
1	F	10 mo	Biliary atresia	LDLT	Left lateral lobe	4
2	F	3 yr	Biliary atresia	LDLT	Left lateral lobe	32
3	F	9 yr	OTCD	Cross-auxiliary double-domino donor liver transplantation	Right lobe	1
4	M	7 mo	Biliary atresia	LDLT	Left lateral lobe	9
5	F	10 mo	Biliary atresia	LDLT	Left lateral lobe	3

LDLT: Living-donor liver transplantation; OTCD: Ornithine transcarbamylase deficiency.

direction. Patients highly suspected of hepatic venous outflow abnormalities through Doppler US examination were subjected to a CT scan. The hepatic venous outflow abnormality was confirmed when the CT scan revealed non-opacification of the hepatic veins, greater than 70% focal luminal narrowing relative to the adjacent normal hepatic vessel in diameter, or a geographic area of low attenuation in the liver, along with clinical symptoms of hepatic congestion (ascites, pleural effusion, elevated liver enzymes, or abnormal findings) on the immediate postoperative Doppler US examination^[3]. The hepatic venous outflow abnormality was further diagnosed by hepatic venography and through pressure measurements in the hepatic vein, inferior vena cava (IVC) and right atrium. Significant hepatic venous outflow stenosis was defined as a pressure gradient > 3 mmHg.

All five patients with hepatic venous outflow abnormalities underwent endovascular angioplasty. The median length of the period from the liver transplantation to the initial procedure was 9.8 mo (range: 1-32 mo). The baseline characteristics of these patients are summarized in Table 1.

Procedures

Each patient or their legal guardian provided written informed consent. The present study was approved by our Institutional Ethics Committee (No. 2017-P2-029-01).

Three authors (Jin L, Chen G, and Su TH., with 22, 21 and 10 years of experience in interventional radiology, respectively) performed these procedures. Percutaneous interventions were performed under general anesthesia in all patients ($n = 5$). Selective hepatic venography and balloon angioplasty were performed *via* the right internal jugular vein. A 0.035-inch hydrophilic guide wire (Terumo, Tokyo, Japan) and 5F cobra catheter (Cook, Bloomington, Indiana) were used to gain entry into the hepatic vein. After hepatic venography, the anastomotic pressure gradient was obtained. After the catheter passed through the desired site, the narrow pressure gradient (right atrium and left hepatic vein) was calculated by recording the intravenous pressure on both sides of the narrowing. Patients with a pressure gradient of > 3 mmHg were considered to have a significant outflow obstruction and were candidates for venoplasty,

in which a percutaneous transluminal angioplasty catheter (Powerflex Plus, Cordis) with a 6- to 8-mm-diameter and 20- to 40-mm-long balloon was utilized. The selection of the balloon was based on the contrast-enhanced CT and venography findings and was matched in size to the vein on the hepatic side of the stenosis. The balloon was laid across the stenosis and was inflated to widen the vein for 60 s at a pressure of 10 atm. Balloon dilation was performed three times, and the effectiveness of the venoplasty was examined by repeated venography and manometric measurements. Hemostasis was achieved by manual compression, without transhepatic track embolization. Patients did not receive heparinization during the whole procedure. Hence, the international normalized ratio was maintained between 1.5-2.0.

Follow-up

The patients' vital signs were monitored in the intensive care unit or general ward every 4-8 h. US was performed one day after the procedure to examine the hepatic venous outflow and to detect post-procedural complications. CT was performed in selected patients within 1 wk after the procedure, according to the physician's need to investigate the hepatic vein and extrahepatic variceal flow and determine any post-procedural complications. Doppler US was performed bimonthly on an outpatient basis, and venography and manometry were performed when recurrent HVOO was suspected.

The following data were retrospectively collected: technical and clinical success, pre- and post-operative pressure gradients across the stenosis, major complications, and patency of the hepatic venous outflow. Technical success was defined as the achievement of a pressure gradient across a stenosis of < 3 mmHg on postprocedural manometry, or a stenosis of < 30% on postprocedural venography. Clinical success was defined as ameliorated signs and symptoms of HVOO, and an improvement in the preprocedural status evaluated by Doppler US^[6]. The definition of a major complication was an event that required extended hospitalization or an advanced level of care^[7].

Statistical analysis

Changes between pre- and post-procedural pressure gradients across the hepatic vein stenosis were




Figure 1 Left lobe graft for biliary atresia in a 2-year-old boy. A: Hepatic venography shows severe blockage of the hepatic venous outflow. The pressure gradient between the right atrium and left vein was 13 mmHg. B: Hepatic venography after percutaneous transluminal venoplasty shows improved flow into the right atrium. The pressure gradient decreased to 3 mmHg.

Table 2 Clinical outcomes following balloon dilatation

Case No.	Vessel	Procedure	Size	Pre-pressure (mmHg)	Post-pressure (mmHg)	Follow-up (mo)
1	HV	PTA	6 mm-4 cm	34/8	13/9	16
2	HV	PTA	8 mm-4 cm	29/7	18/18	16
3	RHV	PTA	8 mm-4 cm	17/10	10/10	1, recurrence
	RHV	PTA	8 mm-4 cm	22/14	15/15	10
4	HV	PTA	8 mm-4 cm	30/17	22/19	33
5	HV	PTA	6 mm-2 cm	17/13	17/15	4
	IVC	PTA	6 mm-2 cm	17/13	14/14	4

HV: Hepatic vein; RHV: Right hepatic vein; IVC: Inferior vena cava; PTA: Percutaneous transluminal angioplasty.

analyzed by paired Student's *t*-test. The analyses were performed using SPSS 21.0 statistical software (IBM, Chicago, IL, United States). A *P*-value < 0.05 was considered statistically significant.

RESULTS

Four liver transplant recipients (one male and three females; age range: seven months to three years old) and one crossed-auxiliary double-domino donor liver transplantation patient (female, nine years old) were diagnosed with HVOO following liver transplantation in the present study (Table 1). The preliminary diagnosis of HVOO was initially assessed by Doppler US and confirmed by subsequent abdominal CT angiography and venography in all five patients. The hepatic vein stenosis rate was 1.62%. The onset of hepatic vein stenosis ranged from 1-32 mo (mean: 9.80 mo) after liver transplantation.

A total of seven procedures were performed for six stenotic lesions in five patients (there were two

anastomoses in one patient, Table 2). The overall technical success rate among these seven procedures was 100% (7/7). A patient with HVOO underwent a balloon angioplasty procedure twice at 15 d after liver transplantation and at one month after liver transplantation due to recurrence. The pressure gradient across the stenotic lesions at the anastomoses ($n = 7$) was 12.0 ± 8.8 mmHg (range: 4-26 mmHg) before balloon dilatation, and this value decreased significantly to 1.1 ± 1.5 mmHg (range: 0-3 mmHg) immediately after the procedure ($P < 0.05$).

Clinical success was achieved in all five patients (100%), as manifested by improved ascites and pleural effusion.

The patients were followed for 4-33 mo (median: 15 mo). The outcomes are shown in Table 2. Among these five patients, four patients were treated by single balloon angioplasty (Figures 1 and 2), and these patients did not develop recurrent stenosis. The patient who underwent two sessions of balloon angioplasty showed no recurrent HVOO for 10 mo during the




Figure 2 Left lobe graft for biliary atresia in a 10-month-old girl. A: The inferior vena cava (IVC) image shows tight fibrotic stenosis at the superior anastomosis close to the right atrium. B: The IVC angiogram after angioplasty with a 6-20 mm balloon shows stricture resolution, no residual stenosis and free flow through the IVC into the right atrium.



Figure 3 A 9-year-old male received cross-auxiliary double-domino donor liver transplantation. One month after the initial procedure, stenosis recurred. A: Hepatic venography shows a stricture at the piggyback hepatic vein anastomosis. B: Hepatic vein angiography after balloon dilatation shows the disappearance of the stricture and free flow through the anastomosis.

subsequent follow-up period (Figure 3). Furthermore, no major procedural complications during any of the seven balloon angioplasty procedures, procedure-related deaths or permanent adverse sequelae occurred.

DISCUSSION

Few cases of HVOO have been reported in pediatric patients following liver transplantation; there have been fewer than ten cases within the past five years.

This study reported our experiences with using balloon dilatation as part of the treatment for HVOO in five children who underwent pediatric liver transplantation, providing valuable reference for the successful treatment of such patients.

HVOO is an infrequent but life-threatening complication following liver transplantation^[8]. Living-donor or auxiliary liver transplantation has been accepted as an effective method to expand the pool of organ donors. At present, technical challenges remain, including HVOO^[8,9]. In the present study, four cases who underwent transplantation at our hospital and one patient who underwent transplantation at another hospital were diagnosed with HVOO. In our center, the incidence of HVOO was 1.62% (4/246), which was lower than the incidences reported at other centers^[10-12]. It has been reported that with the evolution and improvement of surgical techniques, the overall incidence of long-term hepatic vein stenosis has significantly decreased between the eras of 1988 to 1994 and 1995 to 2002^[2]. In the present study, the time to onset of hepatic vein stenosis was 0.5-32 mo (mean: 9.70 mo) after liver transplantation, which was consistent with other studies^[10-12].

At our institution, patients with clinical signs and symptoms of HVOO routinely underwent some forms of noninvasive imaging. Color Doppler US was the most frequently used imaging technique in the present study, providing information on flow direction and velocity. Its results can be made immediately available without the use of ionizing radiation, and it can be conveniently performed at the bedside. Magnetic resonance (MR) venography and CT are excellent alternatives but require scanner availability and sedation in the pediatric population^[13]. Although noninvasive evaluation can aid diagnosis, IVC venography with direct pressure gradient measurement across the suspected lesion is the gold standard for HVOO diagnosis^[4]. In our cases, color Doppler US and enhanced CT findings were supported by the results of venography.

The quantification of the pressure gradient across the stenosis may help verify the significance of the lesion. At present, conflicting opinions exist for the deterministic diagnosis of HVOO through a pressure gradient across the stenotic region between the right atrium and hepatic vein of > 3 mmHg or > 5 mmHg. We recommend the consideration of the diagnosis of HVOO in pediatric recipients with clinical presentations of HVOO, even if their pressure gradients between the right atrium and hepatic vein are < 3 mmHg. A pressure gradient that can sufficiently lead to clinical HVOO may be misleadingly reduced when the patient is ambulatory or lying in the supine position during an operation, leading to a missed or faulty diagnosis. In addition, pressure gradients are typically measured in children under general anesthesia, which affects hepatic and portal vein flow velocities, resulting in the misdiagnosis of HVOO^[11]. In the present study, we recommend measuring the pressure gradient repeatedly

at the same location and as far as possible from the vessel wall. In addition, a diagnostic standard of > 3 mmHg for the pressure gradient is recommended.

At present, endovascular treatment, including percutaneous balloon angioplasty and stent placement, is the preferred treatment for HVOO after liver transplantation^[14]. However, it remains unclear whether balloon angioplasty or stent placement is preferable^[10,11,15]. Kubo *et al.*^[16] performed endovascular treatments in 20 patients with HVOO after liver transplantation. A technically successful balloon venoplasty procedure was initially achieved in all cases. However, 11 (55%) patients had recurrent obstruction, which is suggestive of a high rate of reintervention. Most patients ($n = 10$) were treated by balloon angioplasty, and one patient was rescued by stent placement. The patency rate of the hepatic venous outflow was 1.00 during a follow-up period of 60 mo. Another study reported 10 pediatric patients with HVOO who were treated with stents; after 42 months of follow-up, all stent lumens remained patent. Moreover, the retained stents did not cause profound adverse effects that were harmful to the growth of blood vessels^[12]. Ko *et al.*^[17] performed primary stent placement for early post-transplant HVOO and achieved favorable long-term patency. Overall, the 1-, 3- and 5-year primary patency rates were 82.3%, 75.0% and 72.4%, respectively.

However, many centers hesitate to perform stent placement in children for several reasons^[18]. First, stents are prone to the development of neointimal hyperplasia, leading to recurrent stenosis. Second, a stenotic lesion would be developed when the child matures, since the stent placed has a fixed diameter. Third, the location of the internal stent in children is technically problematic if re-transplantation is required. Finally, the long-term patency of stents remains unknown. The present study demonstrated excellent results for both technical and clinical success (100.0% and 100.0%, respectively) with a low recurrence rate (20%). During the follow-up period, severe complications such as dissection, vascular rupture, thrombosis or death did not occur. More importantly, repeated balloon dilation could achieve satisfactory or even curative outcomes, as shown by our results^[11]. Therefore, we propose that repeated balloon angioplasty can be a primary treatment modality for HVOO in pediatric patients following liver transplantation, even for those with recurrent HVOO.

The individualized selection of balloons (type and size) as well as careful deployment is vital for achieving a desirable outcome. In the present study, the selection of the balloon was based on the experience and skill of the interventional radiologist. We used short balloons (diameter range: 6-8 mm; length: ≤ 4 cm) for all patients. Although the impact of the type and size of the balloon on long-term patency has not been clearly demonstrated, we speculate that a balloon with an appropriate diameter and a short length ensures better long-term patency for treating HVOO in pediatric liver

transplant recipients.

Future directions

Although insufficient evidence has been obtained to support the benefits of stent placement for HVOO, novel stenting devices, such as drug-eluting and biodegradable stents, may be promising for the management of HVOO. Averin *et al.*^[15] reported the use of a customized endovascular stent for the treatment of inferior vena cava obstruction following pediatric liver transplantation, in an attempt to relieve the risk of hepatic venous vein egress. However, the long-term efficacy of endovascular stent placement remains unproven.

Limitation of study

In spite of the technical success and satisfactory clinical outcomes in these five children, the present study had certain limitations, including the retrospective nature of the study, a relatively small sample size, and a relatively short follow-up period. Further studies with a larger sample size that could identify relevant risk factors for HVOO development following transplantation and HVOO recurrence after balloon angioplasty are needed.

In conclusion, balloon dilatation is an effective and safe treatment for HVOO in pediatric patients following liver transplantation, and re-venoplasty is recommended even for patients with recurrent HVOO.

ARTICLE HIGHLIGHTS

Research background

Liver transplantation is the most effective treatment for end-stage liver disease. Hepatic venous outflow obstruction (HVOO) is a severe complication of pediatric liver transplantation, which has a high incidence of 4%-9% owing to the smaller anastomosis diameter and size mismatch of the hepatic vessels between the donor and recipient. Endovascular angioplasty is a less-invasive therapeutic option that has become the first-line treatment option in pediatric transplant recipients. However, it remains controversial whether stent placement or balloon angioplasty is required for patients with HVOO. Rare cases of HVOO have been reported in pediatric patients following liver transplantation. This study reported our experiences with using balloon dilatation as part of the treatment for HVOO in five children subjected to pediatric liver transplantation, providing valuable data for the successful treatment of such patients.

Research motivation

HVOO is a rare and severe complication following pediatric liver transplantation that leads to graft loss in the majority of patients. However, it remains controversial whether stent placement or balloon angioplasty is required for patients with HVOO. This study reported our experiences with using balloon dilatation as part of the treatment for HVOO in five children subjected to pediatric liver transplantation, providing valuable information for the successful treatment of such patients. Balloon dilatation is an effective and safe treatment for HVOO in pediatric patients following liver transplantation, and re-venoplasty is recommended even for patients with recurrent HVOO.

Research objectives

Balloon dilatation is an effective and safe treatment for HVOO in pediatric patients following liver transplantation, and re-venoplasty is recommended even for patients with recurrent HVOO.

Research methods

The authors enrolled a total of 246 pediatric patients who underwent liver transplantation between June 2013 and September 2016. Among these patients, five were ultimately diagnosed with HVOO. Percutaneous interventions were performed under general anesthesia in all patients ($n = 5$). The demographic data, types of donor and liver transplant, interventional examination and therapeutic outcomes of these five children were collected and analyzed with SPSS version 21.0 software. Changes between pre- and post-procedural pressure gradients across the hepatic vein stenosis were analyzed by paired Student's *t*-test.

Research results

The authors found that balloon dilatation is an effective and safe treatment for HVOO in pediatric patients following liver transplantation. The hepatic vein stenosis rate was 1.62%. The time to onset of hepatic vein stenosis ranged from 1-32 mo (mean: 9.80 mo) after liver transplantation. The pressure gradient across the stenotic lesions at the anastomoses before balloon dilatation decreased significantly after the procedure ($P < 0.05$). Sustained follow-up did not reveal significant procedural complications or procedure-related deaths. Further studies with a larger sample size that could identify relevant risk factors for HVOO development following transplantation and HVOO recurrence after balloon angioplasty are needed.

Research conclusions

This study investigated the efficacy and safety of balloon dilatation for the treatment of hepatic venous outflow obstruction following pediatric liver transplantation. HVOO is a rare and severe complication following pediatric liver transplantation that leads to graft loss in the majority of patients. However, it remains unclear whether stent placement or balloon angioplasty is required for patients with HVOO. This study reported our experiences with using balloon dilatation as part of the treatment for HVOO in five children subjected to pediatric liver transplantation, providing valuable information regarding the successful treatment of such patients. Balloon dilatation is an effective and safe treatment for HVOO in pediatric patients following liver transplantation, and re-venoplasty is recommended even for patients with recurrent HVOO. In spite of the technical success and satisfactory clinical outcomes in these five children, the present study had certain limitations, including the retrospective nature of the study, a relatively small sample size, and a short follow-up period. Further studies with a large sample size that could identify risk factors for HVOO development following transplantation and HVOO recurrence after balloon angioplasty are needed.

Research perspectives

This study reported our experiences with using balloon dilatation as part of the treatment for HVOO in five children subjected to pediatric liver transplantation, providing valuable information for the successful treatment of such patients. Balloon dilatation is an effective and safe treatment for HVOO in pediatric patients following liver transplantation, and re-venoplasty is recommended even for patients with recurrent HVOO. In spite of the technical success and satisfactory clinical outcomes in these five children, the present study had certain limitations, including the retrospective nature of the study, a relatively small sample size, and a short follow-up period. Further studies with a large sample size that could identify risk factors for HVOO development following transplantation and HVOO recurrence after balloon angioplasty are needed.

REFERENCES

- 1 **Cheng YF**, Chen CL, Huang TL, Chen TY, Chen YS, Wang CC, Tsang LL, Sun PL, Chiu KW, Eng HL, Jawan B. Angioplasty treatment of hepatic vein stenosis in pediatric liver transplants: long-term results. *Transpl Int* 2005; **18**: 556-561 [PMID: 15819804 DOI: 10.1111/j.1432-2277.2005.00088.x]
- 2 **Buell JF**, Funaki B, Cronin DC, Yoshida A, Perlman MK, Lorenz J, Kelly S, Brady L, Leef JA, Millis JM. Long-term venous complications after full-size and segmental pediatric liver transplantation. *Ann Surg* 2002; **236**: 658-666 [PMID: 12409673]

- DOI: 10.1097/0000658-200211000-00017]
- 3 **Choi JW**, Jae HJ, Kim HC, Yi NJ, Lee KW, Suh KS, Chung JW. Long-term outcome of endovascular intervention in hepatic venous outflow obstruction following pediatric liver transplantation. *Liver Transpl* 2015; **21**: 1219-1226 [PMID: 26197765 DOI: 10.1002/lt.24215]
 - 4 **Lee BB**, Villavicencio L, Kim YW, Do YS, Koh KC, Lim HK, Lim JH, Ahn KW. Primary Budd-Chiari syndrome: outcome of endovascular management for suprahepatic venous obstruction. *J Vasc Surg* 2006; **43**: 101-108 [PMID: 16414396 DOI: 10.1016/j.jvs.2005.09.003]
 - 5 **Fujimori M**, Yamakado K, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Hasegawa T, Sugino Y, Nakajima K, Matsushita N, Mizuno S, Sakuma H, Isaji S. Long-Term Results of Stent Placement in Patients with Outflow Block After Living-Donor-Liver Transplantation. *Cardiovasc Intervent Radiol* 2016; **39**: 566-574 [PMID: 26464222 DOI: 10.1007/s00270-015-1210-4]
 - 6 **Ohm JY**, Ko GY, Sung KB, Gwon DI, Ko HK. Safety and efficacy of transhepatic and transsplenic access for endovascular management of portal vein complications after liver transplantation. *Liver Transpl* 2017; **23**: 1133-1142 [PMID: 28152572 DOI: 10.1002/lt.24737]
 - 7 **Omary RA**, Bettmann MA, Cardella JF, Bakal CW, Schwartzberg MS, Sacks D, Rholl KS, Meranze SG, Lewis CA. Quality improvement guidelines for the reporting and archiving of interventional radiology procedures. *J Vasc Interv Radiol* 2002; **13**: 879-881 [PMID: 12354820 DOI: 10.1016/S1051-0443(07)61769-2]
 - 8 **Chu HH**, Yi NJ, Kim HC, Lee KW, Suh KS, Jae HJ, Chung JW. Longterm outcomes of stent placement for hepatic venous outflow obstruction in adult liver transplantation recipients. *Liver Transpl* 2016; **22**: 1554-1561 [PMID: 27516340 DOI: 10.1002/lt.24598]
 - 9 **Qu W**, Zhu ZJ, Wei L, Sun LY, Liu Y, Zeng ZG. Reconstruction of the Outflow Tract in Cross-Auxiliary Double-Domino Donor Liver Transplantation. *Transplant Proc* 2016; **48**: 2738-2741 [PMID: 27788810 DOI: 10.1016/j.transproceed.2016.07.031]
 - 10 **Yabuta M**, Shibata T, Shibata T, Shinozuka K, Isoda H, Okamoto S, Uemoto S, Togashi K. Long-term outcome of percutaneous interventions for hepatic venous outflow obstruction after pediatric living donor liver transplantation: experience from a single institute. *J Vasc Interv Radiol* 2013; **24**: 1673-1681 [PMID: 24008112 DOI: 10.1016/j.jvir.2013.07.010]
 - 11 **Rao W**, Sun LY, Zhu ZJ, Chen G, Sun XY, Gao W, Shi R. Successful percutaneous transluminal balloon dilatation for hepatic venous outflow obstruction after pediatric liver transplantation: A series of cases. *Hepatol Res* 2013; **43**: 1321-1326 [PMID: 23489344 DOI: 10.1111/hepr.12086]
 - 12 **Carnevale FC**, Machado AT, Moreira AM, De Gregorio MA, Suzuki L, Tannuri U, Gibelli N, Maksoud JG, Cerri GG. Midterm and long-term results of percutaneous endovascular treatment of venous outflow obstruction after pediatric liver transplantation. *J Vasc Interv Radiol* 2008; **19**: 1439-1448 [PMID: 18760627 DOI: 10.1016/j.jvir.2008.06.012]
 - 13 **Lorenz JM**, Van Ha T, Funaki B, Millis M, Leef JA, Bennett A, Rosenblum J. Percutaneous treatment of venous outflow obstruction in pediatric liver transplants. *J Vasc Interv Radiol* 2006; **17**: 1753-1761 [PMID: 17142705 DOI: 10.1097/01.RVI.0000241540.31081.52]
 - 14 **Zhang ZY**, Jin L, Chen G, Su TH, Zhu ZJ, Wei L, Xiao GW. Endovascular interventional therapy of portal vein stenosis after pediatric liver transplantation. *Zhongguo Jieru Yingxiang Yu Zhilixiao* 2017; **14**: 210-213 [DOI: 10.13929/j.1672-8475.201612016]
 - 15 **Averin K**, Bucuvalas J, Alonso MH, Kohli R, Heubi JE, Johnson ND, Goldstein BH. Treatment of Inferior Vena Cava Obstruction Following Pediatric Liver Transplantation: Novel Use of a Customized Endovascular Stent. *J Pediatr* 2017; **180**: 256-260 [PMID: 27793336 DOI: 10.1016/j.jpeds.2016.09.051]
 - 16 **Kubo T**, Shibata T, Itoh K, Maetani Y, Isoda H, Hiraoka M, Egawa H, Tanaka K, Togashi K. Outcome of percutaneous transhepatic venoplasty for hepatic venous outflow obstruction after living donor liver transplantation. *Radiology* 2006; **239**: 285-290 [PMID: 16567488 DOI: 10.1148/radiol.2391050387]
 - 17 **Ko GY**, Sung KB, Yoon HK, Kim JH, Song HY, Seo TS, Lee SG. Endovascular treatment of hepatic venous outflow obstruction after living-donor liver transplantation. *J Vasc Interv Radiol* 2002; **13**: 591-599 [PMID: 12050299 DOI: 10.1016/S1051-0443(07)61652-2]
 - 18 **Sakamoto S**, Egawa H, Kanazawa H, Shibata T, Miyagawa-Hayashino A, Haga H, Ogura Y, Kasahara M, Tanaka K, Uemoto S. Hepatic venous outflow obstruction in pediatric living donor liver transplantation using left-sided lobe grafts: Kyoto University experience. *Liver Transpl* 2010; **16**: 1207-1214 [PMID: 20879019 DOI: 10.1002/lt.22135]

P- Reviewer: Al-Haggag M, Quak SH, Rolle U **S- Editor:** Gong ZM
L- Editor: Wang TQ **E- Editor:** Ma YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

